Cortical thinning in amphetamine-type stimulant users

Neuroscience

Volumn 221, Issue , 2012, Pages 182-192

  Koester, P ^a   Tittgemeyer, M ^b   Wagner, D ^a   Becker, B ^a   Gouzoulis Mayfrank, E ^a   Daumann, J ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Amphetamine; ATS; Cortical thickness; Cortical volume; MDMA; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN REGION; BRAIN SIZE; COMPARATIVE ANATOMY; CONTROLLED STUDY; CORTICAL THINNING; DRUG EXPOSURE; DRUG USE; FEMALE; FRONTAL CORTEX; GRAY MATTER; HEMISPHERIC DOMINANCE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; NEUROANATOMY; OCCIPITAL CORTEX; PARIETAL CORTEX; PRIORITY JOURNAL;

ADULT; AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; ANALYSIS OF VARIANCE; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; YOUNG ADULT;

EID: 84865288301     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.06.049     Document Type: Article

References (64)

1. Alicata D., Chang L., Cloak C., Abe K., Ernst T. Higher diffusion in striatum and lower fractional anisotropy in white matter of methamphetamine users. Psychiatry Res 2009, 174(1):1-8. S0925-4927(09)00087-0 [pii]. 10.1016/j.pscychresns.2009.03.011.
2. Aron J.L., Paulus M.P. Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. Addiction 2007, 102(Suppl. 1):33-43. ADD1778 [pii]. 10.1111/j.1360-0443.2006.01778.x.
3. Brown J., Edwards M., McKone E., Ward J. A long-term ecstasy-related change in visual perception. Psychopharmacology (Berl) 2007, 193(3):437-446. 10.1007/s00213-007-0785-0.
4. Burgess A.P., Venables L., Jones H., Edwards R., Parrott A.C. Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine (" Ecstasy" )/polydrug users. Psychopharmacology (Berl) 2011, 216(4):545-556. 10.1007/s00213-011-2249-9.
5. Coull J.T., Frith C.D., Frackowiak R.S., Grasby P.M. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 1996, 34(11):1085-1095. 0028-3932(96)00029-2 [pii].
6. Cowan R.L., Lyoo I.K., Sung S.M., Ahn K.H., Kim M.J., Hwang J. Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend 2003, 72(3):225-235. S037687160300231X [pii].
7. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999, 9(2):179-194. S1053-8119(98)90395-0 [pii]. 10.1006/nimg.1998.0395.
8. Daumann J., Fischermann T., Heekeren K., Henke K., Thron A., Gouzoulis-Mayfrank E. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) 2005, 180(4):607-611. 10.1007/s00213-004-2002-8.
9. Daumann J., Fischermann T., Heekeren K., Thron A., Gouzoulis-Mayfrank E. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Biol Psychiatry 2004, 56(5):349-355. S0006-3223(04)00676-6 [pii]. 10.1016/j.biopsych.2004.06.011.
10. Daumann J., Koester P., Becker B., Wagner D., Imperati D., Gouzoulis-Mayfrank E. Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry. Neuroimage 2011, 54(2):794-801. S1053-8119(10)01162-6 [pii]. 10.1016/j.neuroimage.2010.08.065.
11. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008, 131(Pt 11):2936-2945. awn255 [pii]. 10.1093/brain/awn255.
12. de Win M.M., Reneman L., Jager G., Vlieger E.J., Olabarriaga S.D., Lavini C. A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology 2007, 32(2):458-470. 1301225 [pii]. 10.1038/sj.npp. 1301225.
13. Dickson C., Bruno R., Brown J. Investigating the role of serotonin in visual orientation processing using an 'ecstasy' (MDMA)-based research model. Neuropsychobiology 2009, 60(3-4):204-212. 000253556 [pii]. 10.1159/000253556.
14. Durazzo T.C., Tosun D., Buckley S., Gazdzinski S., Mon A., Fryer S.L. Cortical thickness, surface area, and volume of the brain reward system in alcohol dependence. relationships to relapse and extended abstinence. Alcohol Clin Exp Res 2011, 35(6):1187-1200. 10.1111/j.1530-0277.2011.01452.x.
15. Easton N., Marsden C.A. Ecstasy: are animal data consistent between species and can they translate to humans?. J Psychopharmacol 2006, 20(2):194-210. 20/2/194 [pii]. 10.1177/0269881106061153.
16. Engvig A., Fjell A.M., Westlye L.T., Moberget T., Sundseth O., Larsen V.A. Effects of memory training on cortical thickness in the elderly. Neuroimage 2010, 52(4):1667-1676. S1053-8119(10)00773-1 [pii]. 10.1016/j.neuroimage.2010.05.041.
17. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000, 97(20):11050-11055. 200033797 [pii]. 10.1073/pnas.200033797.
18. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9(2):195-207. S1053-8119(98)90396-2 [pii]. 10.1006/nimg.1998.0396.
19. Fox H.C., McLean A., Turner J.J., Parrott A.C., Rogers R., Sahakian B.J. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (" ecstasy" ) polydrug users. Psychopharmacology (Berl) 2002, 162(2):203-214. 10.1007/s00213-002-1071-9.
20. Gallinat J., Meisenzahl E., Jacobsen L.K., Kalus P., Bierbrauer J., Kienast T. Smoking and structural brain deficits: a volumetric MR investigation. Eur J Neurosci 2006, 24(6):1744-1750. EJN5050 [pii]. 10.1111/j.1460-9568.2006.05050.x.
21. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction 2006, 101(3):348-361. ADD1314 [pii]. 10.1111/j.1360-0443.2006.01314.x.
22. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of drugs of abuse-the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin Neurosci 2009, 11(3):305-317.
23. Gouzoulis-Mayfrank E., Daumann J., Tuchtenhagen F., Pelz S., Becker S., Kunert H.J. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000, 68(6):719-725.
24. Hall D.A., Stanis J.J., Marquez Avila H., Gulley J.M. A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology (Berl) 2008, 195(4):469-478. 10.1007/s00213-007-0923-8.
25. Hanson K.L., Luciana M., Sullwold K. Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users. Drug Alcohol Depend 2008, 96(1-2):99-110. S0376-8716(08)00071-9 [pii]. 10.1016/j.drugalcdep. 2008.02.003.
26. Hatzidimitriou G., McCann U.D., Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999, 19(12):5096-5107.
27. Hopfinger J.B., Buonocore M.H., Mangun G.R. The neural mechanisms of top-down attentional control. Nat Neurosci 2000, 3(3):284-291. 10.1038/72999.
28. Hutton C., Draganski B., Ashburner J., Weiskopf N. A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage 2009, 48(2):371-380. S1053-8119(09)00679-X [pii]. 10.1016/j.neuroimage.2009.06.043.
29. Kim S.J., Lyoo I.K., Hwang J., Chung A., Hoon Sung Y., Kim J. Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers. Int J Neuropsychopharmacol 2006, 9(2):221-228. S1461145705005699 [pii]. 10.1017/S1461145705005699.
30. Kish S.J., Lerch J., Furukawa Y., Tong J., McCluskey T., Wilkins D. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 2010, 133(Pt 6):1779-1797. awq103 [pii]. 10.1093/brain/awq103.
31. Koechlin E., Hyafil A. Anterior prefrontal function and the limits of human decision-making. Science 2007, 318(5850):594-598. 318/5850/594 [pii]. 10.1126/science.1142995.
32. Koenigs M., Young L., Adolphs R., Tranel D., Cushman F., Hauser M. Damage to the prefrontal cortex increases utilitarian moral judgements. Nature 2007, 446(7138):908-911. nature05631 [pii]. 10.1038/nature05631.
33. Kolb B., Gorny G., Li Y., Samaha A.N., Robinson T.E. Amphetamine or cocaine limits the ability of later experience to promote structural plasticity in the neocortex and nucleus accumbens. Proc Natl Acad Sci U S A 2003, 100(18):10523-10528. 1834271100 [pii]. 10.1073/pnas.1834271100.
34. Koob G.F., Simon E.J. The neurobiology of addiction: where we have been and where we are going. J Drug Issues 2009, 39(1):115-132.
35. Kuhn S., Schubert F., Gallinat J. Reduced thickness of medial orbitofrontal cortex in smokers. Biol Psychiatry 2010, 68(11):1061-1065. S0006-3223(10)00818-8 [pii]. 10.1016/j.biopsych.2010.08.004.
36. Lawyer G., Bjerkan P.S., Hammarberg A., Jayaram-Lindstrom N., Franck J., Agartz I. Amphetamine dependence and co-morbid alcohol abuse: associations to brain cortical thickness. BMC Pharmacol 2010, 10:5. 1471-2210-10-5 [pii]. 10.1186/1471-2210-10-5.
37. Makris N., Gasic G.P., Kennedy D.N., Hodge S.M., Kaiser J.R., Lee M.J. Cortical thickness abnormalities in cocaine addiction-a reflection of both drug use and a pre-existing disposition to drug abuse?. Neuron 2008, 60(1):174-188. S0896-6273(08)00706-X [pii]. 10.1016/j.neuron.2008.08.011.
38. Martin G.L., Newman I.M. Assessing the validity of self-reported adolescent cigarette smoking. J Drug Educ 1988, 18(4):275-284.
39. Mechtcheriakov S., Brenneis C., Egger K., Koppelstaetter F., Schocke M., Marksteiner J. A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007, 78(6):610-614. jnnp. 2006.095869 [pii]. 10.1136/jnnp.2006.095869.
40. Melega W.P., Raleigh M.J., Stout D.B., Lacan G., Huang S.C., Phelps M.E. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 1997, 766(1-2):113-120. S0006-8993(97)00548-9 [pii].
41. Moeller F.G., Hasan K.M., Steinberg J.L., Kramer L.A., Valdes I., Lai L.Y. Diffusion tensor imaging eigenvalues: preliminary evidence for altered myelin in cocaine dependence. Psychiatry Res 2007, 154(3):253-258. S0925-4927(06)00198-3 [pii]. 10.1016/j.pscychresns.2006.11.004.
42. Moeller F.G., Steinberg J.L., Lane S.D., Buzby M., Swann A.C., Hasan K.M. Diffusion tensor imaging in MDMA users and controls: association with decision making. Am J Drug Alcohol Abuse 2007, 33(6):777-789. 783770469 [pii]. 10.1080/00952990701651564.
43. Morgan M.J., Impallomeni L.C., Pirona A., Rogers R.D. Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naive controls. Neuropsychopharmacology 2006, 31(7):1562-1573. 1300953 [pii]. 10.1038/sj.npp. 1300953.
44. Ornstein T.J., Iddon J.L., Baldacchino A.M., Sahakian B.J., London M., Everitt B.J. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000, 23(2):113-126. S0893-133X(00)00097-X [pii]. 10.1016/S0893-133X(00)00097-X.
45. Patenaude B (2007) Bayesian Statistical Models of Shape and Appearance for Subcortical Brain Segmentation. Thesis.
46. Patenaude B., Smith S., Kennedy D., Jenkinson M. FIRST - FMRIB's integrated registration and segmentation tool 2007, Paper presented at the Human Brain Mapping Conference.
47. Patenaude B., Smith S., Kennedy D., Jenkinson M. Improved Surface Models for FIRST 2008, Paper presented at the Human Brian Mapping Conference.
48. Paulus M.P., Hozack N., Frank L., Brown G.G., Schuckit M.A. Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. Biol Psychiatry 2003, 53(1):65-74. S0006322302014427 [pii].
49. Paulus M.P., Tapert S.F., Schuckit M.A. Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Arch Gen Psychiatry 2005, 62(7):761-768. 62/7/761 [pii]. 10.1001/archpsyc.62.7.761.
50. Quednow B.B., Kuhn K.U., Hoppe C., Westheide J., Maier W., Daum I. Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA (" Ecstasy" ). Psychopharmacology (Berl) 2007, 189(4):517-530. 10.1007/s00213-005-0256-4.
51. Ricaurte G.A., Martello A.L., Katz J.L., Martello M.B. Lasting effects of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 1992, 261(2):616-622.
52. Rogers R.D., Everitt B.J., Baldacchino A., Blackshaw A.J., Swainson R., Wynne K. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 1999, 20(4):322-339. S0893133X98000918 [pii]. 10.1016/S0893-133X(98)00091-8.
53. Rothe M., Pragst F., Spiegel K., Harrach T., Fischer K., Kunkel J. Hair concentrations and self-reported abuse history of 20 amphetamine and ecstasy users. Forensic Sci Int 1997, 89(1-2):111-128. S0379-0738(97)00123-0 [pii].
54. Schoenbaum G., Roesch M.R., Stalnaker T.A. Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci 2006, 29(2):116-124. S0166-2236(05)00324-3 [pii]. 10.1016/j.tins.2005.12.006.
55. Schoenbaum G., Shaham Y. The role of orbitofrontal cortex in drug addiction: a review of preclinical studies. Biol Psychiatry 2008, 63(3):256-262. S0006-3223(07)00534-3 [pii]. 10.1016/j.biopsych.2007.06.003.
56. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(Suppl 1):S208-219. S1053-8119(04)00393-3 [pii]. 10.1016/j.neuroimage.2004.07.051.
57. Tanabe J., Tregellas J.R., Dalwani M., Thompson L., Owens E., Crowley T. Medial orbitofrontal cortex gray matter is reduced in abstinent substance-dependent individuals. Biol Psychiatry 2009, 65(2):160-164. S0006-3223(08)00971-2 [pii]. 10.1016/j.biopsych.2008.07.030.
58. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 2004, 24(26):6028-6036. 24/26/6028 [pii]. 10.1523/JNEUROSCI.0713-04.2004.
59. UNODC (2011) 2011 Global ATS Assessment. United Nations Publication, http://www.unodc.org/documents/ATS/ATS_Global_Assessment_2011.pdf.
60. Valdes I.H., Steinberg J.L., Narayana P.A., Kramer L.A., Dougherty D.M., Swann A.C. Impulsivity and BOLD fMRI activation in MDMA users and healthy control subjects. Psychiatry Res 2006, 147(2-3):239-242. S0925-4927(06)00021-7 [pii]. 10.1016/j.pscychresns.2006.01.014.
61. Volkow N.D., Fowler J.S., Wang G.J., Baler R., Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(Suppl. 1):3-8. S0028-3908(08)00148-2 [pii]. 10.1016/j.neuropharm.2008.05.022.
62. Woolrich M.W., Jbabdi S., Patenaude B., Chappell M., Makni S., Behrens T. Bayesian analysis of neuroimaging data in FSL. Neuroimage 2009, 45(Suppl. 1):S173-186. S1053-8119(08)01204-4 [pii]. 10.1016/j.neuroimage.2008.10.055.
63. Yamamoto B.K., Moszczynska A., Gudelsky G.A. Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 2010, 1187:101-121. NYAS5141 [pii]. 10.1111/j.1749-6632.2009.05141.x.
64. Zolkowska D., Rothman R.B., Baumann M.H. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther 2006, 318(2):604-610. jpet.106.101618 [pii]. 10.1124/jpet.106.101618.